Sionna Therapeutics, Inc. (NASDAQ:SION) Given Average Recommendation of “Moderate Buy” by Analysts

Sionna Therapeutics, Inc. (NASDAQ:SION) has been assigned an average rating of “Moderate Buy” from the thirteen research firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $53.2222.

A number of analysts have recently issued reports on SION shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday, May 8th. UBS Group reaffirmed a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Stifel Nicolaus boosted their price objective on Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a report on Monday, May 18th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $63.00 price objective on shares of Sionna Therapeutics in a report on Tuesday, May 26th.

Sionna Therapeutics Stock Performance

Shares of NASDAQ SION opened at $37.78 on Friday. Sionna Therapeutics has a 1 year low of $13.51 and a 1 year high of $48.44. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -19.58 and a beta of 1.30. The stock’s 50-day simple moving average is $40.50 and its 200-day simple moving average is $39.92.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, research analysts predict that Sionna Therapeutics will post -2.57 EPS for the current year.

Insider Activity

In related news, Director Peter A. Thompson sold 184,639 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. The trade was a 6.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,717,962 shares of company stock valued at $77,571,889. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of Sionna Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of SION. Eventide Asset Management LLC bought a new stake in Sionna Therapeutics in the fourth quarter valued at about $26,290,000. Vanguard Group Inc. increased its holdings in Sionna Therapeutics by 81.4% in the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after buying an additional 512,803 shares during the last quarter. State Street Corp grew its holdings in shares of Sionna Therapeutics by 188.7% during the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after purchasing an additional 453,196 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Sionna Therapeutics by 30.1% during the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after purchasing an additional 335,942 shares during the last quarter. Finally, Viking Global Investors LP grew its holdings in shares of Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the last quarter.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.